hotspot -WSS

hotspot

author：knowledge 2025-09-30 05:04:05 - browse：7

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Roche drug slashes death risk in early

leisure time

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Roche acquires Telavant from Roivant, adding experimental IBD treatment

FDA reorg will put new emphasis on investigations, sources say

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Why a market frenzy over new weight loss drugs defies logic

entertainment

hotspot

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

STAT Summit: How researchers deal with rejection

Medical records are filled with copy

Type 2 diabetes prevention programs work at large scale: study

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Continuity nursing helped my family in our darkest PICU moments

Study suggests Covid rebound is far more common with Paxlovid than without

State Dept. review finds Biden bears some blame for Afghanistan failures

After decades in use, heart stents finally beat placebo

Wikipedia

STAT Summit: Ending the crisis of Black deaths in the U.S.

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Results on Novartis prostate cancer therapy could expand its use

Study suggests Covid rebound is far more common with Paxlovid than without

J&J lung cancer data amount to new salvo against AstraZeneca

After decades in use, heart stents finally beat placebo

leisure time

explore

focus

explore